Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Change in Acquisitions & Divestments (2016 - 2026)

Oramed Pharmaceuticals filings provide 15 years of Change in Acquisitions & Divestments readings, the most recent being $28.8 million for Q4 2025.

  • Quarterly Change in Acquisitions & Divestments fell 52.08% to $28.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $54.4 million through Dec 2025, down 43.95% year-over-year, with the annual reading at $54.4 million for FY2025, 43.95% down from the prior year.
  • Change in Acquisitions & Divestments hit $28.8 million in Q4 2025 for Oramed Pharmaceuticals, up from $21.0 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $124.2 million in Q3 2022 and bottomed at -$121.1 million in Q4 2022.
  • Average Change in Acquisitions & Divestments over 5 years is $9.1 million, with a median of $3.1 million recorded in 2021.
  • Peak annual rise in Change in Acquisitions & Divestments hit 4530.99% in 2024, while the deepest fall reached 8815.38% in 2024.
  • Oramed Pharmaceuticals' Change in Acquisitions & Divestments stood at $953000.0 in 2021, then crashed by 12808.71% to -$121.1 million in 2022, then surged by 101.34% to $1.6 million in 2023, then soared by 3601.66% to $60.2 million in 2024, then crashed by 52.08% to $28.8 million in 2025.
  • Per Business Quant, the three most recent readings for ORMP's Change in Acquisitions & Divestments are $28.8 million (Q4 2025), $21.0 million (Q3 2025), and $3.7 million (Q2 2025).